Compare First Citizens BancShares Inc (FCNCA) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Citizens BancShares Inc vs IDEXX Laboratories, Inc. — how do they compare? First Citizens BancShares Inc trades at $2,278.08 (market cap $25.04B), while IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and First Citizens BancShares Inc pays a 0.37% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| FCNCA | IDXX | |
|---|---|---|
Market Cap | $25.04B | $46.22B |
Sector | Sector/Thematic | Health |
52-Week High | $2.25K | $766.68 |
52-Week Low | $1.64K | $526.44 |
Dividend Yield | 0.37% | — |
Enterprise Value | — | $47.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Citizens BancShares (FCNCA) trades at $2,276, up 1.91% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 12.08 and net income margin of 25.23%, supported by recent earnings beats. Recent news highlights business expansion, including new financing groups and real estate acquisitions.
Outlook is positive with analyst consensus price target of $2,310, though most analysts rate it Hold. Key risks include elevated uninsured deposits and net interest margin pressure. Earnings growth and strategic initiatives provide upside potential, but investor caution is warranted near current levels.
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Citizens BancShares Inc
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
